Danaher Corporation (NYSE:DHR) is one of the best strong buy healthcare stocks to buy now. On July 23, UBS lowered the firm’s ...

Danaher Corp (DHR) reports robust free cash flow and bioprocessing growth, while navigating global trade tensions and Life ...

Danaher Corporation thrives on bioprocessing demand and diagnostics resilience. Click for why, with solid execution and 80% ...

Danaher (NYSE:DHR) stock falls even as the company beats Q2 2025 forecasts despite an underperformance at its Life Sciences ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Danaher ( (DHR) ) has issued an update.

Danaher Corp (NYSE:DHR) on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the ...

Danaher Corporation’s DHR second-quarter 2025 adjusted earnings of $1.80 per share beat the Zacks Consensus Estimate of $1.64 ...

Insights from Steven Cohen (Trades, Portfolio)'s First Quarter 2025 13F Filing. Warning! GuruFocus has detected 4 Warning ...

Danaher reported generating $1.1 billion in free cash flow during the quarter, with adjusted diluted net earnings per share increasing by approximately 5% year-over-year. This financial strength ...

Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Matthew Gugino, currently Group Chief Financial Officer of the Company's Life Sciences ...

The stock's fall snapped a two-day winning streak.

This was the stock's third consecutive day of losses.